Copy Link Print Information

Ralpancizumab

Customer Review

Based on 1 Customer Validation

Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.

For research use only. We do not sell to patients.

  • Purity : 96.23%
  • CAS No.: 1407495-04-8
  • Molecular Weight:145.28 kDa
  • Storage:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Ralpancizumab
  • Experimental Validation Results for Ralpancizumab
  • Experimental Validation Results for Ralpancizumab
  • Ralpancizumab Chemical Structure
    Ralpancizumab Chemical Structure
CAS No.: 1407495-04-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Ralpancizumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG2 kappa

  • 1/16

    Immobilized PCSK9 Protein, Human (HEK293, C-His, HY-P70545A) can bind Ralpancizumab. The EC50 for this effect is 963.6 ng/mL.

  • 1/16

    Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Ralpancizumab (anti-PCSK9) (HY-P99816). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Ralpancizumab Chemical Structure
    1/16
  • Ralpancizumab
  • Immobilized PCSK9 Protein, Human (HEK293, C-His, HY-P70545A) can bind Ralpancizumab. The EC50 for this effect is 963.6 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Ralpancizumab (anti-PCSK9) (HY-P99816). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).